Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out the conference call next week. It will be very interesting I'm sure.
-Fritz
That's kind of a stunner. They have been describing themselves as an oncology company off and on in their corporate PRs for a while now since Helen came on board, so there's that. OTOH where is the cash for acquisitions going to come from? One could guess that they are extremely confident in the outcome of the current phase III and that the money taps will be flowing freely after that.
Beyond that, I'm pretty surprised to say the least. Anybody else have any thoughts?
HALO's weird new job posting:
-------------------------------
Vice President, Corporate Development
POSITION SUMMARY:
The Vice President, Oncology Business Development will report to the CEO and, in partnership with the Executive Team, will define and execute Halozyme’s plan to build a multi-product oncology company. S/he will drive the company’s growth strategy through the identification, evaluation, execution, and integration of compelling acquisition and investment opportunities complementary to our two pillar business.
ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:
These may include but are not limited to:
Develop a vision for a Halozyme oncology portfolio that will excite and engage investors
Lead execution of diligence, detailed assessment and valuation of oncology companies and assets identified as potentially attractive for Halozyme to access
Lead and execute the end-to-end M&A process, including identification of key value drivers during diligence, creation, and execution of the integration plan and monitoring and reporting of and business objectives
Recommend approach and terms for acquisition/licensing of new assets
Lead process for evaluation, selection and negotiation with regional partners
Develop valuation model for potential regional partnerships opportunities
Establish internal process for rapid search and evaluation for identification of new asset opportunities and newly emerging competitive threats and as we build our portfolio
Cultivate robust network with banks, companies, and opinion leaders to facilitate deal identification and consummation
Manage reporting of asset’s long-term value, operational achievements, risks, and dependencies; proactively identify potential planning gaps, suggest mitigation's to open issues/risks and drive resolutions
Create integration processes/playbooks that incorporate prior experience and industry best practices across the cross-functional team
ADDITIONAL FUNCTIONS AND RESPONSIBILITIES:
Identify new ENHANZE opportunities and new platform technologies and communicate these to ENHANZE Business Development team
Other duties as assigned
EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES:
A minimum of a Bachelor’s degree with at least 15 years’ business development experience within the biopharmaceutical industry (and equivalent combination of education and experience may be considered)
Demonstrated track record of success leading a range of transactions including company or asset acquisition, out-licensing assets and mergers and acquisitions
Proven experience playing major role on transactions in pharma/biotech
Previous experience as an investor or working within Private Equity Group assessing and making recommendations on acquisitions of companies or assets
Former scientific and commercialization expertise in oncology
Expert level skills building deal models
Deep knowledge of US and EU markets; Asia Pac experience, a plus
MS, PhD, MD, CFA or MBA preferred
TECHNICAL KNOWLEDGE REQUIRED:
Equipment: PC, scanners, facsimile machine, voice mail and e-mail systems, and common office machines, or ability to be trained.
Software Knowledge : Windows, MS Office (Outlook, Word, Excel, PowerPoint, Visio)
INTERNAL AND EXTERNAL RELATIONSHIPS:
Develop internal and external relationships that successfully drive business objectives
Collaborate with cross-functional teams consisting of functional experts and target company leaders throughout the M&A process
EFFORT REQUIRED/ENVIRONMENTAL CONDITIONS:
Physical Activities : On a continuous basis, sit at desk for a long period of time; intermittently answer telephone and write or use a keyboard to communicate through written means. Some walking and lifting up to 20 lbs. may be required. The noise level in the work environment is usually low to moderate. The physical demands described above are representative of those that must be met by an employee to successfully perform the essential functions and responsibilities of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions and responsibilities.
Laboratory Activities, if applicable: Biology and chemical laboratory environments experience needed. Environmental health and safety requirements also apply.
TRAVEL:
Travel may be required up to 50% of your time
I calculate that about 85% of HALO shares are locked up in large money vaults. That is probably why the pps doesn't move much when good news comes out like the recent partnership. The big boys are essentially all waiting for the cancer leg to clarify itself. Their patience is instructive.
-Fritz
Right. Good catch. It appears that the open interest in the Feb16s is diminishing so he looks like he's rolling them out to March 17's. Stay tuned.
-Fritz
That guy was definitely trading on inside information. He will be lucky if he breaks even at around $17. I bet he thought he'd make a killing. Plus he has to worry that the SEC will come-a-calling since his move was so obvious. He might be out of reach, though, if he is in Belgium which I suspect.
-Fritz
That guy was definitely trading on inside information. He will be lucky if he breaks even at around $17. I bet he thought he'd make a killing. Plus he has to worry that the SEC will come-a-calling since his move was so obvious. He might be out of reach, though, if he is in Belgium which I suspect.
-Fritz
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients.
Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive mid-single digit royalties on sales of commercialized products.
"Through our collaboration with Halozyme, a company that has transformed subcutaneous delivery of biologics, we now have the potential to add optimal delivery capabilities to our profile of building best-in-class antibodies against novel targets. By gaining exclusive access to ENHANZE® technology for our anti-FcRn asset, we also solidify our leadership position in this exciting new space that has the potential to disrupt the way severe autoimmune diseases are treated," commented Keith Woods, Chief Operating Officer of argenx. "As we look towards commercialization, if approved, efgartigimod is now equipped with a well-established subcutaneous delivery technology in addition to the clinical activity and favorable tolerability profile we have observed in studies to date. We believe that by offering both intravenous and subcutaneous formulations, we have the opportunity to capture patient preferences across all indications within our efgartigimod portfolio."
"We are excited to work with argenx to create new delivery options for therapies being developed to improve the lives of patients suffering from severe autoimmune diseases," said Dr. Helen Torley, president and CEO of Halozyme. "This collaboration is an example of the value ENHANZE® can potentially bring while a product is still in development where the benefits of subcutaneous administration can be realized earlier by both patients and healthcare providers."
argenx represents Halozyme's ninth global collaboration and license partner for the ENHANZE® technology. These collaborations cover more than 50 therapeutic targets and include three commercialized products.
https://finance.yahoo.com/news/argenx-halozyme-enter-global-collaboration-060000672.html
Totally agree.
I think it's fair to say that the next six months are going to be quite interesting.
-Fritz
Couldn't hold $3 for more than a minute. Glad I got out of this a while ago.
-Fritz
That's an interesting theory that makes a lot of sense, especially in the current mode where volume has been very low and the vast majority of shares are fairly locked up.
-Fritz
Right, somebody suddenly holds options on about half a million shares at $16 per share. The average price today was about a dollar per share again. (In addition, I like the way the chart is setting up as an inverse head and shoulders.) Why this person is buying Feb 16 calls I do not know. But buying he is.
-Fritz
Chartwise, looks like a nice inverse head and shoulders pattern setting up, FWIW.
-Fritz
The average price was about $.95 for the calls so it was a bet of about $220,000. It might be nothing as you mentioned but an interesting tidbit to keep in mind for the next few weeks.
-Fritz
Somebody just placed a big bet on Feb 16 calls.
Agreed on the upside. Thanks for your thoughts.
-Fritz
Thanks for the update. Any discussion about new partners?
I'll give it a listen in a day or so.
-Fritz
It's still a risk but the loss of the cancer program, the worst case scenario, will still leave a very profitable company based on the enhanze platform.
-Fritz
Yes, after listening to the call I felt that there was little reason to panic. The big money obviously felt the same. Volume the next day after the call was really a tell.
Good luck!
-Fritz
HALO- Your thoughts make sense to me at least because Helen Torley did mention yesterday that the primary benefit to the statistical change would be seen farther to the right of the curve and this is good for their prospects because the earlier studies showed pegph20 offered more survival benefit differential further out in time.
-Fritz
I agree that the issue here is that the PFS trial design was flawed and they have wisely chosen to clean it up in the manner announced today. I personally don't see this necessary change as a good or bad harbinger of things to come. My assessment of the risks is still the same today as it was yesterday. The news will, however, certainly peeve investors who are now essentially looking at another year of waiting.
Good luck,
-Fritz
How would you interpret this, Dew?
Thanks,
-Fritz
Thx, Dew, have a great turkey day. [eom]
RVNC: when is the next inflection point generally anticipated?
Thanks!
-Fritz
HALO institutional ownership 84%. Thrivent Financial took a new position of 2.3 million shares.
https://www.nasdaq.com/symbol/halo/institutional-holdings
As I understand it, that is decidedly bearish.
https://www.investopedia.com/ask/answers/06/putcallratio.asp
Good luck!
-Fritz
Interesting. Roche is Swiss, so there's that...
-Fritz
I see LRAD finally made it to $3 after I gave up on them. I hope that you profited, TH.
-Fritz
I was impressed by the tone of Laurie Selzer's announcement that we will definitely be inking more colaborative agreements. They are usually pretty coy about that stuff unless something is imminent, IMHO. I'd expect at least one other before year's end. Just speculation of course.
Good luck!
-Fritz
Interesting. I think it's time for Novartis to step up and see what a partnership with Halozyme has to offer. They are one of the few big pharma players not to have done so yet.
Good luck!
-Fritz
Between BMY and Roche, HALO just put $30 million in the bank this month.
Halozyme will receive a nomination fee for each of the two additional new target nominations.
To be exact, the deal is for 1 Target and the option for 2 more.
-Fritz
I guess they are still not selling many ZNoses. The latest product (Titanium Pyro Reduction Furnace (Ti-PRF))they are touting is so laughable it sounds like it was invented at Marvel Comix.
-Fritz
The best P&D schemes, I have learned, always put an effort into showing that they have an actual business. These in the end are just theatrical props to act as lures for the victim investors. The fact that they had actual jeans and shirts and a website is not evidence that it was legit. This is a lesson learned for me. The tuition in the School of Hard Knocks is expensive! LOL!
Good luck!
-Fritz
Halo Licenses New ENHANZE® Deal with Roche For $25 Million Upfront Payment, Future Milestones And Royalties
Tuesday 30 October 2018
SAN DIEGO, Oct. 30, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of a new undisclosed clinical stage therapeutic target, with an option to select two additional targets within four years.
Under terms of the agreement, Halozyme will receive an upfront fee of $25 million with the potential to earn additional payments of up to $160 million to $165 million per target subject to achievement of specified development, regulatory and sales-based milestones. Additionally, Halozyme will receive a nomination fee for each of the two additional new target nominations. Halozyme will also receive mid-single digit royalties on sales of commercialized products. The company expects to recognize the initial $25 million payment in the fourth quarter of 2018.
"I am delighted to announce another further expansion of our long-term relationship with Roche, covering the selection of these three new targets," said Dr. Helen Torley, president and CEO. This agreement is a strong illustration of our strategy to unlock and grow ENHANZE value through supporting partners in advancing more promising targets into the clinic through the expansion of existing agreements and the addition of new ones."
The Halozyme/Roche relationship dates back to the original global collaboration and licensing agreement for the ENHANZE technology signed in 2006. Under this agreement, Roche developed Rituxan® SC ex-U.S., Rituxan Hycela® in the U.S., Herceptin® SC ex-U.S., is awaiting an FDA action date in 2019 for Herceptin SC in the U.S., and is conducting a Phase 3 study for the fixed dose combination of Perjeta®/Herceptin SC. In addition, Roche is in Phase 1 testing with an undisclosed target. More recently, in 2017, the relationship expanded to include the right to evaluate an additional target with ENHANZE.
The Halozyme ENHANZE technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan -- a glycosaminoglycan or chain of natural sugars in the body -- to aid in the dispersion and absorption of other injected therapeutic drugs. For Halozyme partners, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.
https://www.halozyme.com/investors/news-releases/news-release-details/2018/Halozyme-Licenses-New-ENHANZE-Targets-For-25-Million-Upfront-Payment-Future-Milestones-And-Royalties/default.aspx
HALO Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Bristol-Myers Squibb (NYSE: BMY) has dosed the first subject in a clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, using Halozyme's proprietary ENHANZE® drug delivery technology.
"Since the signing of our collaboration with Bristol-Myers Squibb in September 2017, we have formed multiple joint program teams and have made rapid progress to begin assessment of ENHANZE with Bristol-Myers Squibb's extensive immuno-oncology portfolio," said Dr. Helen Torley, president and chief executive officer of Halozyme. "In addition to their initial selection of the PD-1 targeted asset, Bristol-Myers Squibb has chosen to evaluate BMS-986179 in combination with ENHANZE in certain cancers. We look forward to continuing our pursuit of improving the patient treatment experience."
Initiation of the study triggered a $5 million milestone payment to Halozyme under the Collaboration and License Agreement between the companies.
Your investment is lost if you hold much longer, but take heart it could be a tax loss against any gains you might see in a legitimate company. Also, it is tuition paid in your investment education so hopefully you will use this experience to recognize future scams like this and avoid being ripped off. It is not a tragedy unless you fail to learn from it.
Good luck!
-Fritz
This scam is now thoroughly exposed.
Read all of my posts here over the last few months. The bottom is falling out and was entirely predictable, especially since this is the third time around for these thieves. Time for a perp walk for management.